Article information
La osteoporosis en el varón ha sido tradicionalmente infravalorada, aunque supone un problema de salud de primer orden. Sus consecuencias son tanto o más graves que en la mujer. Además, la osteoporosis complica el curso de una gran cantidad de enfermedades endocrinas. En el presente artículo se revisan los aspectos etiopatogénicos, diagnósticos y terapéuticos más novedosos que pueden ser de interés en el manejo de la osteoporosis del varón.
Palabras clave:
Osteoporosis
Varón
Etiología
Diagnóstico
Tratamiento
Male osteoporosis has been typically neglected; nevertheless it is a major medical problem. Male osteoporosis is, at least, as serious as menopausal osteoporosis. On the other hand, male osteoporosis is a common complication in many endocrinological diseases. In the present article, recent advances in physiopathology, diagnosis and treatment will be reviewed.
Key words:
Osteoporosis
Male
Etiology
Diagnosis
Therapy
Full text is only aviable in PDF
Bibliografía
[1.]
M.E. Farmer, L.R. White, J.A. Brody, K.R. Bailey.
Race and sex differences in hip fracture incidence.
Am J Public Health, 74 (1984), pp. 1374-1380
[2.]
T.V. Nguyen, J.A. Eisman, P.J. Kelly, P.N. Sambrook.
Risk factors for osteoporotic fractures in elderly men.
Am J Epidemiol, 144 (1996), pp. 255-263
[3.]
L.J. Melton III, E.A. Chrischilles, C. Cooper, A.W. Lane, B.L. Riggs.
How many women have osteoporosis?.
J Bone Miner Res, 7 (1992), pp. 1005-1010
[4.]
J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, J.A. Eisman.
Mortality after all major types of osteoporotic fracture in men and women: an observational study.
Lancet, 353 (1999), pp. 878-882
[5.]
G.M. Kiebzak, G.A. Beinart, K. Perser, C.G. Ambrose, S.J. Siff, M.H. Heggeness.
Undertreatment of osteoporosis in men with hip fracture.
Arch Intern Med, 162 (2002), pp. 2217-2222
[6.]
E. Seeman.
Sexual dimorphism in skeletal size, density, and strength.
J Clin Endocrinol Metab, 86 (2001), pp. 4576-4584
[7.]
E.S. Orwoll.
Osteoporosis in men.
Primer on the metabolic bone diseases and disorders of mineral metabolism, 5.ª ed, pp. 360-364
[8.]
J.P. Bonjour, G. Theintz, B. Buchs, D. Slosman, R. Rizzoli.
Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence.
J Clin Endocrinol Metab, 73 (1991), pp. 555-563
[9.]
J.S. Finkelstein, A. Klibanski, R.M. Neer.
A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty.
J Clin Endocrinol Metab, 81 (1996), pp. 1152-1155
[10.]
M.N. Moreira-Andres, F.J. Cañizo, F.J. De la Cruz, A. Gomez-de la Camara, F.G. Hawkins.
Bone mineral status in prepubertal children with constitutional delay of growth and puberty.
Eur J Endocrinol, 139 (1998), pp. 271-275
[11.]
C.W. Slemenda, J.C. Christian, T. Reed, T.K. Reister, C.J. Williams, C.C. Johnston Jr.
Long-term bone loss in men: effects of genetic and environmental factors.
Ann Intern Med, 117 (1992), pp. 286-291
[12.]
N. Ortego-Centeno, M. Muñoz-Torres, E. Jodar, J. Hernandez-Quero, A. Jurado-Duce, J. De la Higuera Torres-Puchol.
Effect of tobacco consumption on bone mineral density in healthy young males.
Calcif Tissue Int, 60 (1997), pp. 496-500
[13.]
P. Lips, D. Vitamin.
deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications.
Endocrinol Rev, 22 (2001), pp. 477-501
[14.]
P.J. Kelly, N.A. Pocock, P.N. Sambrook, J.A. Eisman.
Dietary calcium, sex hormones, and bone mineral density in men.
BMJ, 300 (1990), pp. 1361-1364
[15.]
C. Snow-Harter, R. Whalen, K. Myburgh, S. Arnaud, R. Marcus.
Bone mineral density, muscle strength, and recreational exercise in men.
J Bone Miner Res, 7 (1992), pp. 1291-1296
[16.]
A. Rapado, F. Hawkins, L. Sobrinho, M. Diaz-Curiel, A. Galvao-Telles, S. Arver, et al.
Bone mineral density and androgen levels in elderly males.
Calcif Tissue Int, 65 (1999), pp. 417-421
[17.]
M. Muñoz-Torres, E. Jodar, M. Quesada, F. Escobar-Jimenez.
Bone mass in androgen-insensitivity syndrome: response to hormonal replacement therapy.
Calcif Tissue Int, 57 (1995), pp. 94-96
[18.]
M. Sosa, E. Jodar, E. Arbelo, C. Domínguez, P. Saavedra, A. Torres, et al.
Bone mass, bone turnover, vitamin D, and estrogen receptor gene polymorphisms in male to female transsexuals: effects of estrogenic treatment on bone metabolism of the male.
J Clin Densitom, 6 (2003), pp. 297-304
[19.]
S. Khosla, L.J. Melton 3rd, E.J. Atkinson, W.M. O’Fallon.
Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.
J Clin Endocrinol Metab, 86 (2001), pp. 3555-3561
[20.]
E.S. Orwoll, R.F. Klein.
Osteoporosis in men.
Endocrinol Rev, 16 (1995), pp. 87-116
[21.]
E. Seeman.
Pathogenesis of bone fragility in women and men.
Lancet, 359 (2002), pp. 1841-1850
[22.]
Finkelstein JS. Overview of osteoporosis in men. En: Rose BD, editor. Up to Date. Wellesley: 2006
[23.]
D. Vanderschueren, S. Boonen, R. Bouillon.
Osteoporosis and osteoporotic fractures in men: A clinical perspective.
Baillieres Best Pract Res Clin Endocrinol Metab, 14 (2000), pp. 299-315
[24.]
E. Seeman.
Estrogen, androgen, and the pathogenesis of bone fragility in women and men.
Curr Osteoporos Rep, 2 (2004), pp. 90-96
[25.]
E. García Fernández, S. Guadalix Iglesias, H. Requejo Salinas, E. Jodar Gimeno, F. Hawkins Carranza.
Esteroides sexuales y hueso: ¿tiene sexo el hueso?.
REEMO, 14 (2005), pp. 5-14
[26.]
Petrone E, Goldman R, Calis K, Chrousos GP, Cizza G. Glucocorticoid-induced osteoporosis. Basic mechanisms and clinical implications. En: Chrousos G editor. Adrenal physiology and diseases. Endotext. [Consultado 3 enero 2007]. http://www.endotext.org/adrenal/adrenal7/adrenalframe7.htm
[27.]
Jodar E. Osteoporosis inducida por corticoides. En: Controversias en osteoporosis. Díez-Pérez A, editor. Barcelona: SEIOMM, MMC; 2006 [en prensa]
[28.]
H. Spencer, N. Rubio, E. Rubio, M. Indreika, A. Seitam.
Chronic alcoholism. Frequently overlooked cause of osteoporosis in men.
Am J Med, 80 (1986), pp. 393-397
[29.]
P. Bataille, J.M. Achard, A. Fournier, B. Boudailliez, P.F. Westeel, N. El Esper, et al.
Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers.
Kidney Int, 39 (1991), pp. 1193-1205
[30.]
Jodar E. Hipercalcemia e hiperparatiroidismo primario. En: Arboleya L, editor. Guía práctica de enfermedades del metabolismo óseo y mineral. Madrid: Adalia Farma; 2006 [en prensa].
[31.]
Jodar E, Martínez G, Hawkins F. Tirotoxicosis y osteoporosis. Osteomail: A fondo. 2004;4.
[32.]
M. Muñoz-Torres, E. Jodar, F. Escobar-Jiménez, P.J. López-Ibarra, J.D. Luna.
Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus.
Calcif Tissue Int, 58 (1996), pp. 316-319
[33.]
Hordon LD. Bone disease in diabetes mellitus. En: Rose BD, editor. UpToDate. Waltham: 2005.
[34.]
T. Ueland.
Bone metabolism in relation to alterations in systemic growth hormone.
Growth Horm IGF Res, 14 (2004), pp. 404-417
[35.]
K.E. Ensrud, R.L. Fullman, E. Barrett-Connor, J.A. Cauley, M.L. Stefanick, H.A. Fink, et al.
Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study.
J Clin Endocrinol Metab, 90 (2005), pp. 1998-2004
[36.]
P. Szulc, F. Munoz, F. Duboeuf, F. Marchand, P.D. Delmas.
Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study.
Osteoporos Int, 16 (2005), pp. 1184-1192
[37.]
E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, et al.
Alendronate for the treatment of osteoporosis in men.
N Engl J Med, 343 (2000), pp. 604-610
[38.]
E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, et al.
The effect of teriparatide human parathyroid hormone (1-34) therapy on bone density in men with osteoporosis.
J Bone Miner Res, 18 (2003), pp. 9-17
[39.]
E. Toth, E. Csupor, S. Meszaros, V. Ferencz, L. Nemeth, E.V. McCloskey, et al.
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures –an open label study.
Bone, 36 (2005), pp. 47-51
[40.]
J.D. Adachi, W.G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, et al.
Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
N Engl J Med, 337 (1997), pp. 382-387
[41.]
D.M. Reid, R.A. Hughes, R.F.J.M. Laan, N.A. Sacco-Gibson, D.H. Wenderoth, S. Adami, et al.
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial.
J Bone Miner Res, 15 (2000), pp. 1006-1013
[41.]
E.S. Kurland, F. Cosman, D.J. McMahon, C.J. Rosen, R. Lindsay, J.P. Bilezikian.
Therapy of idiopathic osteoporosis in men with parathyroid hormone: Effects on bone mineral density and bone markers.
J Clin Endocrinol Metab, 85 (2000), pp. 3069-3076
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición